Compare GSK plc (GSK) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares MSCI India ETF — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while iShares MSCI India ETF trades at $48.73. The key difference: GSK plc pays a 3.49% dividend while iShares MSCI India ETF pays none, and GSK plc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| GSK | INDA | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $55.29 |
52-Week Low | $36.20 | $45.42 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
INDA, the iShares MSCI India ETF, trades at $48.66 with a slight 0.14% decline. Technical indicators show a bearish bias with moving averages signaling caution, though the RSI at 29.30 suggests potential oversold conditions. The ETF tracks India's stock market, which remains the world's fastest-growing large economy with 7.8% GDP growth reported for Q1 2026 (CNBC, 2026-06-05). Recent news highlights India's AI opportunities and banking sector strength amid foreign investor outflows.
The outlook for INDA hinges on India's robust economic growth offsetting near-term headwinds like foreign capital outflows and IT sector weakness. Investment appeal lies in exposure to a high-growth economy at a reasonable valuation (P/E of 20.5x per Seeking Alpha, 2026-06-03), but risks include Middle East tensions impacting inflation and stricter grid rules challenging clean energy investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
